Universal’s new $ 34 million-backed MedRhythms partnership will see its music used to treat neurological damage
Universal Music Group (UMG) has signed what it calls a one-of-a-kind partnership with digital therapy company MedRhythms, which allows the latter company to access UMG’s catalog for the purpose of delivering music on prescription to patients.
MedRhythms creates âdirect stimulation solutionsâ that use clinical-grade sensors, software and music to help restore function lost due to neurological disease or injury.
The company’s platform is based on neuroscience that demonstrates how music can impact the human brain, target specific neural circuits to improve clinical outcomes, and stimulate neuroplasticity.
MedRhythms is well funded, having closed a $ 25 million Series B financing round in July co-led by Morningside Ventures and Advantage Capital. The company has raised a total of $ 34 million in gross private finance proceeds since its inception.
MedRhythms’ digital therapies use music content that is organized and filtered through the company’s patented process, which selects and personalizes interventions for each user.
The process initially scans the content for the right characteristics to make it therapeutically useful for patients and, once this step is completed, arranges clinical interventions for each patient.
MedRhythms and UMG are the first companies to develop an FDA-approved prescription music platform.
MedRhythms is developing a patented platform for evidence-based digital prescription therapies using music to treat walking disorders.
This platform is based on neuroscience research showing that auditory rhythm can be used to directly target the human motor system to address walking deficits caused by neurological injury and disease, including stroke, multiple sclerosis. plaques (MS), Parkinson’s disease (PD), Alzheimer’s disease and cognitive impairment and aging in place.
Due to early positive results from clinical trials, MedRhythms flagship product MR-001 for people with chronic gait deficits after stroke has received Revolutionary device designation from the United States Federal Drug Administration (FDA) for its potential to provide more effective treatment for life-threatening or irreversible debilitating diseases.
In addition to enabling MedRhythms to provide prescription music to patients, Universal Music Group for Brands, UMG’s global brand partnering team, will provide MedRhythms with data analytics resources and insights, cultural intelligence and marketing.
UMG’s partnership with MedRhythms began as a collaboration between UMG for Brands and Havas Health.
UMG debuted on the Amsterdam Stock Exchange last Tuesday (September 21), with a market cap of $ 54 billion.
âMusic has the power to transcend borders, cultures and languages ââto connect people and improve the quality of life around the world. Now with MedRhythms, we see the power of music harnessed to heal.
Michael Nash, UMG
Michael Nash, Executive Vice President of Digital Strategy at UMG, said: âMusic has the power to transcend borders, cultures and languages ââto connect people and improve the quality of life around the world.
âNow with MedRhythms, we see the power of music harnessed to heal. Our innovative collaboration with MedRhythms will allow UMG to help improve neurological treatment for patients across the United States.
âWe have played a central role in promoting the growing importance of music in the health and wellness industry – fitness, sleep, meditation – and in this pioneering alliance we have the privilege of committing to extend the profound impact of music to medical therapy. “
âThe partnership with UMG is an important step for MedRhythms which will open countless doors to improve the quality of care we provide to patients. “
Brian Harris, MedRhythms
Brian Harris, CEO and Co-Founder of MedRhythms, said: âThe partnership with UMG is an important step for MedRhythms which will open countless doors to improve the quality of care we provide to patients.
âWe are honored to collaborate with the world’s leaders in music entertainment and match this with our world-class scientific team to continue to push the boundaries of music and medicine while having a significant impact on the lives of patients who desperately in need of this care. This partnership will give us the opportunity to leverage patient favorite music to deliver the best clinical results and create a product that patients are excited to use. “
Music trade around the world